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CASE REPORT

Fatal Autoimmune Storm After a Single Cycle of
Anti-PD-1 Therapy: A Case of Lethal Toxicity but
Pathological Complete Response in Metastatic
Lung Adenocarcinoma
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Abstract
As immunotherapy agents are incorporated into the routine oncological practice, the number of patients at the risk of
immune-related adverse events has increased dramatically. However, the prompt identiﬁcation and effective management of severe autoimmune complications remain a challenge. We report the case of a patient with metastatic lung
adenocarcinoma who experienced a fatal autoimmune storm 3 weeks after the ﬁrst dose of anti-programmed death receptor-1 (PD-1) agent pembrolizumab, which included thyroiditis, hepatitis, myositis, myocarditis, pneumonitis, and
myasthenia gravis. Aggressive autoimmunity was supported by extensive T-cell and macrophage tissue inﬁltrates and
autoantibody positivity. Remarkably, no residual tumor was found at autopsy. This case illustrates the potential harm
caused by immunotherapy and our limited knowledge on its prevention, treatment, and association to antitumor efﬁcacy.
Keywords: Immune-related adverse events, Immunotherapy, Lung adenocarcinoma, Myasthenia gravis, Myocarditis,
Myositis, PD-1/PD-L1

1. Introduction

T

he advent of immunotherapy has revolutionized modern oncology because of unprecedented durable clinical beneﬁts and better safety
proﬁles. Immune checkpoint inhibitors (ICIs), the
most widely available type of cancer immunotherapy, aim to prevent the ability of cancer cells to
evade the immune system by interfering with
cytotoxic T-lymphocyte antigen-4 (CTLA-4), or
programmed death receptor-1 (PD-1) and its ligand
(PD-L1). Immune-related adverse events (irAEs)
resulting from ICI therapy are common and

frequently not severe enough to lead to treatment
interruptions [1]. However, in some cases severe
irAEs can result in patient death. Here we report a
case of a patient with metastatic lung adenocarcinoma who died after a cascade of severe autoimmunity and who had no residual tumor disease
following a single cycle of anti-PD-1 agent
pembrolizumab.

2. Methods
Systematical gross and immunohistochemical
postmortem studies were performed to identify the
extent and cellular composition of inﬂammatory

Received 25 August 2019; revised 28 March 2020; accepted 5 April 2020.
Available online 1 March 2022
* Corresponding authors at: Department of Medical Oncology, Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, S/N, 28040 Madrid,
Spain.
E-mail address: jfuentesa@salud.madrid.org (J. Fuentes-Antr
as).
1
These authors contributed equally to the manuscript.
https://doi.org/10.1016/j.hemonc.2020.04.006
2589-0646/© 2022 King Faisal Specialist Hospital and Research Centre. This is an open access article under the CC-BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

64

HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY 2022;15:63e67

inﬁltrates. Blood samples were drawn at presentation for autoantibody testing. Autoantibodies were
studied with indirect immunoﬂuorescence on HEp2 human carcinoma cells line (HELIOS autoanalyzer, Aesku, Wendesheilm, Germany), Luminex
automated technique (Bioplex 2200, Bio-Rad, Hercules, California, USA), and enzyme-linked immunosorbent assay (Triturus, Grifols, Barcelona,
Espa~
na) based on manufacturer’s recommendations
(Table 1). Human leukocyte antigen (HLA) typing
was assessed using Luminex technology. Peripheral
blood lymphocyte subsets were determined using
ﬂow cytometry (BD Biosciences, San Jose, CA, USA).
The study was conducted with the approval of the
Ethics Committee of the Hospital Clínico San Carlos, Madrid, Spain.
2.1. Case report
A 75-year-old Caucasian male patient was diagnosed with metastatic lung adenocarcinoma, negative for EGFR, ALK, and ROS alterations and
positive for PD-L1 in 70% of tumor cells (Dako,
Glostrup, Denmark). As ICIs were not approved for
ﬁrst-line therapy at that time, the patient received
ﬁrst-line chemotherapy with the combination of
carboplatin, paclitaxel, and bevacizumab, followed
by maintenance treatment with bevacizumab until
disease progression. Since the patient had an
excellent performance status and no history of
autoimmune disorders, pembrolizumab regimen
was initiated.
After 3 weeks, the patient presented to our ofﬁce
with severe asthenia, myalgia, profuse sweating,
and palpitations. Routine blood tests showed primary hyperthyroidism along with grade 2 hepatic
cytolysis, and thyroiditis was found in thyroid
scintigraphy (Fig. 1A). Treatment was interrupted,
and the patient initiated symptomatic therapy with
oral propranolol. At the follow-up visit a week later,
symptoms were aggravated with blurred vision and
diplopia. Diagnostic workup during hospitalization
showed grade 4 hepatotoxicity and an increase of

free T4 value (Fig. 1B). The suspicion of autoimmune
thyrotoxicosis and hepatitis led to the initiation of
high-dose dexamethasone (4 mg every 6 hours),
methimazole, and propranolol. After the ﬁrst intravenous (IV) dose of propranolol, the patient suffered
a syncopal episode. An electrocardiogram revealed
a complete atrioventricular block (Fig. 1C), thus
requiring the implantation of a pacemaker at the
Coronary Unit. Concurrently, serum analyses
exhibited increased creatine kinase, creatine kinaseMB (Muscle and Brain subunits), and troponin-I
(Fig. 1B). The patient recovered well after the procedure but experienced a rapid decline of respiratory function and psychomotor agitation 24 hours
later. Neurological examination evidenced bilateral
ptosis, oculomotor palsy, proximal muscular weakness, dysphonia, and dysphagia. A cranial
computed tomography scan was performed displaying no abnormalities. Given the presumptive
diagnosis of myasthenia gravis (MG) and myositis,
the patient was started on pyridostigmine and 1 g IV
methylprednisolone bolus daily for the following 5
days. The progressive impairment of ventilatory
mechanics led to global respiratory insufﬁciency.
Inﬂiximab 5 mg/kg and intravenous immunoglobulins (IVIGs) were added to the treatment 48 hours
later. Noninvasive mechanical ventilation was initiated but poorly tolerated, and the decision of
limiting the therapeutic effort was taken together
with family members, with death occurring at Day 7
of hospitalization.
A comprehensive immunological assessment
before intensive steroid therapy rendered positive
serum antibodies against acetylcholine receptors
(AChRs), thyroglobulin, thyroid peroxidase (TPO),
striated muscles, and mitochondria (Fig. 2AeE and
Table 1). Cell blood count revealed grade 2 lymphopenia, with ﬂow cytometry immunophenotyping showing only CD19þ 83 cells/mL, NK 154 cells/
mL, and an inverted CD4/CD8þ T-cell ratio. Additionally, the patient was found to be homozygous for
HLA B51. Postmortem examinations revealed multiorgan damage associated to extensive inﬁltration

Table 1. Positive autoantibodies.
Autoantibody

Technique

Titers (if available)

Normal range (if applicable)

Clinical association

Thyroglobulin
Thyroid peroxidase
Mitochondria (M2)
Acetylcholine receptor
Striated muscle
SSA (Ro)
PM/Scl100
SRP

ELISA
ELISA
IIF, Immunoblot
ELISA
IIF
Immunoassay, Immunoblot
Immunoassay, Immunoblot
Immunoassay, Immunoblot

355 U/mL
393 U/mL
High
12.8 nmol/L

0e150
0e75

Dysthyroidism
Dysthyroidism
Hepatitis
Myasthenia gravis
Myositis
Myositis
Myositis
Myositis

0e0.5

ELISA ¼ enzyme-linked immunosorbent assay; IIF ¼ indirect immunoﬂuorescence; SRP ¼ signal recognition particle.
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Fig. 1. Clinical presentation and course. (A) Thyroid scintigraphy showing an enlarged gland with irregular iodine uptake compatible with thyroiditis.
(B) Time course of serum liver aminotransferases, thyroxine, cardiac enzymes, and creatine kinase along with main clinical events and treatments
during hospitalization. (C) An electrocardiogram showing complete atrioventricular block.

by CD8þ T-lymphocytes and histiocytes: necrotizing myocarditis, lymphocytic thyroiditis with
follicular destruction and thyroid atrophy, necrotizing myopathy, and bilateral focal pneumonitis

(Fig. 2FeH). By contrast, the liver remained free of
macroscopic alterations. Surprisingly, no evidence
of adenocarcinoma was observed after thorough
scrutiny of the lungs and prior sites of metastasis

Fig. 2. Main histological and immunological features. (AeD) Liver autoimmunity in indirect immunoﬂuorescence. Anti-mitochondrial M2 antibodies
showing differential cytoplasmic granular ﬂuorescence of the proximal tubules in rodent kidney (A), liver hepatocytes (B), and parietal and chief cells
(C, D). (E) Anti-striated muscle staining by indirect immunoﬂuorescence. (FeH) Autopsy ﬁndings. (F) Myocardium: necrotic changes and CD8þ Tlymphocyte and histiocyte inﬁltrates. (G) Striated muscle: necrotic changes, CD8þ (CD45þ, CD3þ, CD8þ) T-lymphocyte inﬁltrates together with
myophagocytosis (CD68þ). (H) Thyroid gland: multinodular, CD8þ T-lymphocyte inﬁltrates with extensive destruction of thyroid follicles.
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(left adrenal gland, and mediastinal and retroperitoneal lymph nodes).

3. Discussion
Prior to immunotherapy, the patient had an
excellent performance score and no history of
autoimmune disorders or associated signs/symptoms, underscoring the detrimental impact of a
therapy considered less harmful than standard
chemotherapy regimens.
Neurological complications are rare (1e3%) in
patients undergoing ICI therapy, seem dose- and
drug-independent, occur at early stages of treatment, and may include myastheniform manifestations [2,3]. A comprehensive review of 23 patients
with immune-mediated MG reported a death rate of
30%, with increased anti-AChR antibodies in almost
all cases [4]. Importantly, myositis and/or myocarditis occur concomitantly with MG, and frequently
related to poor outcomes [5]. Consistent with previous data, anti-striated muscle antibodies were
positive in our patient (Fig. 2H), along with antibodies against Ro52, SRP, and PM/Scl100 [6]. AntiSRP antibodies have been linked to necrotizing
autoimmune myopathy, a ﬁnding which was
conﬁrmed in muscle histology (Fig. 2B) [7].
Immune-related hepatitis appears with an estimated incidence of 1e4% with anti-PD-1/PD-L1
therapy [8]. Serum anti-mitochondrial antibodies
were detected in our patient (Fig. 2DeG), which are
speciﬁc for primary biliary cirrhosis but can also be
found in patients with autoimmune hepatitis [9].
Intriguingly, no histological alterations were spotted
on postmortem liver study. Elevated serum transaminases are not uncommonly present in severe
myositis and may have been the reason for the
normal liver ﬁndings. We also hypothesize that liver
damage beneﬁted from early high-dose steroids
given the progressive amelioration of aminotransferase levels throughout hospitalization. As for hyperthyroidism, incidence seems to be around 10%
with the use of anti-PD-1/PD-L1 agents [10]. Our
patient displayed high titers of anti-thyroid peroxidase and thyroglobulin antibodies, which is consistent with a recent series showing anti-thyroid
antibodies in 80% of patients experiencing immunotherapy-related dysthyroidism [11].
Additional immunological evaluation revealed an
inverted CD4/CD8þ T-cell ratio. While lymphopenia is a common irAE (9% grade 3e4), an inverted
CD4þ/CD8þ T-cell ratio likely suggests an
unleashed activation of cytotoxic T cells. When
exploring genetic patterns of subclinical autoimmune disorders, our patient was identiﬁed as a

homozygous carrier of HLA B51. This haplotype
confers a considerably high risk for Behçet disease,
although our patient had no medical history of
Behçet’s associated signs and/or symptoms [12].
Moreover, HLA B51 does not seem to inﬂuence
treatment response according to recent investigations, contrasting with the absence of tumor
disease at autopsy [13]. We hypothesize that an association exists between the explosive autoimmune
activation and the exceptional antitumor efﬁcacy.
Consistently, overall survival has been found
extended in patients with melanoma and non-small
cell lung cancer who experienced irAEs [14,15].
The low number of immunotherapy-related MG
cases hampers the elaboration of effective management guidelines. Steroid therapy may transiently
interfere with respiratory homeostasis and trigger a
myasthenic crisis, which is why steroids should be
delivered in combination with IVIG and/or plasmapheresis rather than in monotherapy [16]. Also,
steroid dose largely diverge in the literature from
prednisone 1 mg/kg daily to 1 g methylprednisolone
bolus [4]. In refractory cases, additional therapy with
anti-TNF inhibitors (i.e., inﬂiximab) may be
considered, although it is supported by scant evidence on immune-related colitis [17]. Future therapeutic approaches may be based on the use of
agents such as abatacept, which interferes with the
second signal of the immune synapse by targeting
CD28/CD80-CTLA-4 [18].
In conclusion, this report aims to highlight the
importance of an early recognition of potentially
fatal immune toxicities elicited by immunotherapy
and calls for the standardization of therapeutic
strategies. Following a single cycle of ICI therapy,
our patient presented with hyperthyroidism and
mild hepatotoxicity, but rapidly progressed to
myocarditis, pneumonitis, MG, and death despite
the use of intensive steroid and immunosuppressive
therapies. Both cellular and humoral immune responses were involved as revealed by extensive
CD8þ inﬁltrates in autopsy, an inverted CD4þ/
CD8þ ratio of circulating T cells, and positive serum
antibodies against AChRs, thyroglobulin, TPO,
striated muscles, and mitochondria. To the best of
our knowledge, this is the only clinical report
describing the coexistence of multiple severe irAEs
and a pathological complete response in metastatic
lung adenocarcinoma. An urgent need exists to gain
further insight into genetic and immune signatures
that can help stratify patients according to the risk of
developing severe irAEs and also to increase our
understanding on the role of irAEs as a surrogate of
a hyperactive immune system and improved antitumoral outcomes.
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